WE CAN HELP
December 31, 2015
Epizyme announces first patient dosed in global clinical program. Dana Farber Cancer Institute and Cincinnati Children's Hospital are the first sites activated for pediatric enrollment.
The study of tazemetostat offers a possible treatment for INI1-negative tumors, including AT/RT, when no other treatments are available. Read More
Welcome to the new Cure ATRT Now website. When we started Cure ATRT Now, it was just a few frightened parents frustrated by the scarcity of informatio...
October 3, 2015
Epizyme Research Update
November 6, 2017
New Research Suggests Potential Therapeutic Targets
March 6, 2016
Epizyme launches dosing program
New Research Posted
December 30, 2015
Epizyme European Cancer Conference Recap
September 28, 2015
FDA Accepts Drug in Phase 1 study INI1-Negative Tumors, Including AT/RT
August 24, 2015
What is AT/RT Cancer?
August 6, 2015
Phase 1 Dose Escalation Shows Promise
November 20, 2014